ALDERIA INTELLIGENCE

Cardiometabolic intelligence

Stay ahead of the cardiometabolic space.

Research, clinical trials, and regulatory decisions from 12+ global markets. Curated daily, decoded for pharma executives and investors.

Try for free

Recent signals

View all →
Pick of the weekClinicalTrials17 Apr 2026·Phase 3● 8/10i

The Effect of Semaglutide in Subjects With Non-cirrhotic Non-alcoholic Steatohepatitis

Phase 3 trial evaluates semaglutide versus placebo in adults with non-cirrhotic NASH, measuring steatohepatitis resolution, fibrosis improvement, and cirrhosis-free survival over approximately 5 years. The study enrolled 1,205 adults and is active but not recruiting, with completion expected in 2029. This represents Novo Nordisk's push into NASH, a major unmet need with no approved GLP-1 therapies despite strong preclinical rationale. The trial's dual primary endpoints and 5-year duration suggest preparation for a pivotal regulatory filing in this large addressable market.

GLP-1Liver/NASHNovo Nordisk

What to watch

Upcoming events and decisions that could move the market.

Q2 2026

Amgen MariTide Phase 3 readout

Phase 3 obesity trial primary endpoint data expected. Could redefine competitive landscape for injectable GLP-1 alternatives.

Amgen
Apr 2026

EMA CHMP opinion on tirzepatide CV label expansion

Expected CHMP opinion on cardiovascular indication for tirzepatide. Key reimbursement trigger in several EU5 markets.

Eli Lilly
Mid-2026

Novo Nordisk CagriSema Phase 3 obesity data

Phase 3 results for cagrilintide/semaglutide combination. Could set a new efficacy benchmark in obesity pharmacotherapy.

Novo Nordisk
ClinicalTrials17 Apr 2026·Phase 3● 8/10iHigh impactPick of the week

The Effect of Semaglutide in Subjects With Non-cirrhotic Non-alcoholic Steatohepatitis

Phase 3 trial evaluates semaglutide versus placebo in adults with non-cirrhotic NASH, measuring steatohepatitis resolution, fibrosis improvement, and cirrhosis-free survival over approximately 5 years. The study enrolled 1,205 adults and is active but not recruiting, with completion expected in 2029. This represents Novo Nordisk's push into NASH, a major unmet need with no approved GLP-1 therapies despite strong preclinical rationale. The trial's dual primary endpoints and 5-year duration suggest preparation for a pivotal regulatory filing in this large addressable market.

GLP-1Liver/NASHNovo Nordisk
ClinicalTrials17 Apr 2026·Phase 3● 8/10iHigh impact

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

Phase 3 trial evaluating retatrutide for chronic low back pain in people with obesity or overweight, targeting dual primary endpoints of pain intensity reduction and weight loss. 586-person placebo-controlled study expected to complete September 2027, investigating a novel indication beyond traditional metabolic endpoints. Eli Lilly is exploring pain management as a potential expansion for their triple agonist, representing the first major trial of a GLP-1-based therapy specifically for chronic pain conditions.

GLP-1Weight lossOtherEli Lilly
ClinicalTrials17 Apr 2026·Phase 3● 8/10iHigh impact

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease

Phase 3 cardiovascular outcomes trial testing orforglipron versus placebo in people with established atherosclerotic cardiovascular disease and/or chronic kidney disease. Event-driven study enrolling 7,140 participants with expected completion in August 2031, approximately 5 years duration. This positions Eli Lilly to compete directly with Novo Nordisk's cardiovascular claims for semaglutide by establishing orforglipron as the first small-molecule oral GLP-1 with proven cardiovascular benefits. The trial targets a high-risk population already established for GLP-1 cardiovascular benefit validation.

GLP-1CardiovascularEli Lilly
ClinicalTrials17 Apr 2026·Phase 3● 8/10iHigh impact

A Phase 3, Open-Label Study of Once Daily LY3502970 Compared With Insulin Glargine in Adult Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Phase 3 open-label trial compared once-daily oral orforglipron versus insulin glargine in people with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study enrolled 2,749 participants with primary endpoint of time to first major adverse cardiovascular event, completed in March 2026. Eli Lilly is positioning orforglipron as a cardiovascular outcomes option in high-risk populations, directly competing with established insulin therapy in this indication. This represents the first cardiovascular outcomes trial for orforglipron following its April 2026 FDA approval for type 2 diabetes.

GLP-1Type 2 diabetesWeight lossCardiovascularEli Lilly
ClinicalTrials16 Apr 2026·Phase 3● 8/10iHigh impact

A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes

Phase 3 master protocol testing oral orforglipron versus placebo in adults with obesity or overweight, with or without type 2 diabetes. Enrolling 1,200 participants across two sub-studies, expected completion August 2027, placebo-controlled design. Eli Lilly advances orforglipron into obesity treatment following its April 2026 FDA approval for type 2 diabetes, representing the first small-molecule oral GLP-1 to enter weight management. This positions Eli Lilly to challenge Novo Nordisk's dominance in oral GLP-1 obesity treatment, where oral semaglutide gained approval in January 2026.

GLP-1Weight lossType 2 diabetesEli LillyNovo Nordisk
PubMed19 Apr 2026·Obesity (Silver Spring, Md.)● 6/10i

Prevalence of Preclinical and Clinical Obesity Among US Children and Adolescents Aged 5 to 18 Years: NHANES 2017-2023.

One in five US youth aged 5-18 have obesity using the new Lancet Diabetes & Endocrinology Commission framework, with 12.5% having clinical obesity that includes physiological dysfunction. Cross-sectional analysis of NHANES 2017-2023 data from 5,513 youth, comparing traditional BMI percentile classification with the new framework that incorporates waist-to-height ratio and clinical impairments. This provides the first US population-level data applying the new obesity framework that shifts focus from BMI alone to physiological dysfunction, potentially expanding the pediatric population eligible for medical intervention. The analysis reveals limitations in routinely collected clinical data for implementing the new classification system in practice.

Weight lossReal-world evidence

Weekly briefing

Key signals, decoded for pharma executives and investors. Free, every week.

Try for free